Published in:
Open Access
01-12-2018 | Research article
Acute biliary events during anti-tuberculosis treatment: hospital case series and a nationwide cohort study
Authors:
Lih-Yu Chang, Chih-Hsin Lee, Chia-Hao Chang, Ming-Chia Lee, Meng-Rui Lee, Jann-Yuan Wang, Li-Na Lee
Published in:
BMC Infectious Diseases
|
Issue 1/2018
Login to get access
Abstract
Background
Tuberculosis (TB) remains one of the major infectious diseases worldwide. Adverse reactions are common during TB treatment. Few reports, however, are available on treatment-related acute biliary events (ABEs), such as cholelithiasis, biliary obstruction, acute cholecystitis, and cholangitis.
Methods
We first report four pulmonary TB patients who developed ABEs during anti-TB treatment. Abdominal sonography revealed multiple gall stones with dilated intrahepatic ducts in three patients and cholecystitis in one patient. To investigate the incidence of and risk factors for ABEs during anti-TB treatment, we subsequently conducted a nationwide cohort study using the National Health Insurance Research Database of Taiwan.
Results
A total of 159,566 pulmonary TB patients were identified from the database between 1996 and 2010, and among them, 195 (0.12%) developed ABEs within 180 days after beginning anti-TB treatment. Logistic regression analysis revealed that the risk factors associated with ABEs are older age (relative risk [RR]: 1.32 [1.21–1.44] per 10-year increment) and diabetes mellitus (RR: 1.59 [1.19–2.13]).
Conclusions
Although infrequently encountered, ABEs should be considered among patients with TB who experience abdominal discomfort with hyperbilirubinemia, especially patients who have older age or diabetes.